文献リスト

1）Bernal WA, Hyyrylainen A, Gera A, et al. Lessons from look-back in acute liver failure?　A single centre experience of 3300 patients. J Hepatol. 2013; 59: 74-80

2）Karkhanis JE, Verna EC, Chang MS, et al. Steroid use in acute liver failure. Hepatology. 2014; 59: 612-21

3）Stravitz RT, Sanyal AJ, Reisch J, et al. Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival. Liver Int. 2013; 33: 1324-31

4）Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013; 369: 2525-34

5）Rastogi A, Maiwall R, Bihali C, et al. Two-tier regenerative response in liver failure in humans. Virchows Arch. 2014; 464: 565-73

6）Salehi S, Brereton HC, Amo MJ, et al. Human liver regeneration is characterized by the coordinated expression of distinct microRNA governing cell cycle fate. Am J Transplant. 2013; 13: 1282-95

7）Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology. 2014; 59: 2092-100

8）Ye H, Zhang XW, Mu R, et al. Anti-TNF therapy in patients with HBV infection--analysis of 87 patients with inflammatory arthritis. Clin Rheumatol. 2014; 33: 119-23

9）Lee YH, Bae SC, Song GG, et al. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2013; 31: 118-21

10）Nakamura J, Nagashima T, Nagatani K, et al. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2014 Apr 4. [Epub ahead of print]

11）van der Have M, Oldenburg B, Fidder HH, et al. Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-alpha inhibitors in Crohnʼs disease. Dig Dis Sci. 2014; 59: 554-63

12）Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014; 343: 1221-8

13）持田　智，中山伸朗．我が国における急性肝不全および遅発性肝不全(LOHF)の実態(2012年)－平成24年度全国調査－．厚生労働省科学研究費補助金（難治性疾患克服対策事業）「難治性の肝・胆道疾患に関する調査研究班」平成25年度報告書．2014. p.131-46

14）Leise MD, Poterucha JJ, Talwalkar JA, et al. Drug-induced liver injury. Mayo Clin Proc. 2014; 89: 95-106

15）Bunchorntavakul C, Reddy KR. Herbal and dietary supplement hepatotoxicity. Aliment Pharm Ther. 2013; 37: 3-17

16）Patel SS, Beer S, Kearney DL, et al. Green tea extract: a potential cause of acute liver failure. World J Gastroenterol. 2013; 19: 5174-7

17）Jaeschke H, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev. 2012; 44: 88-106

18）Han D, Dara L, Win S, et al. Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends Pharmacol Sci. 2013; 34: 243-53

19）Pessayre D, Fromenty B, Berson A, et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 2012; 44: 34-87

20）鈴木一幸，滝川康裕，片岡晃二郎，他．早期搬送システム確立後の肝炎重症化要因の検討．厚生労働省科学研究費補助金（難治性疾患克服対策事業）「難治性の肝・胆道疾患に関する調査研究班」平成25年度報告書．2014. p.152-9

21）Antoine DJ, Lewis PS, Goldring CE, et al. Are we closer to finding biomarkers for identifying acute drug-induced liver injury. Biomaerkers Med. 2013; 7: 383-6

22）Starkey LPJ, Dear J, Platt V, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology. 2011; 54: 1767-76

23）Bel LN, Vuppalanchi R, Watkins PB, et al. Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharm Ther. 2012; 35: 600-12

24）Sturgeon JP, Shawcross DL. Recent insights into the pathogenesis of hepatic encephalopathy and treatments. Expert Rev Gastroenterol Hepatol. 2014; 8: 83-100

25）Tranah TH, Vijay GK, Ryan JM, et al. Systemic inflammation and ammonia in hepatic encephalopathy. Metab Brain Dis. 2013; 28: 1-5

26）Thumburu KK, Dhiman RK, Vasishta RK. Expression of astrocytic genes coding for proteins implicated in neural excitation and brain edema is altered after acute liver failure. J Neurochem. 2014; 128: 617-27

27）Ryan JM. Acute liver failure and the brain: a look through the crystal ball. Metab Brain Dis. 2013; 28: 7-10

28）Edwards L, Wanless IR. Mechanism of liver involvement in systemic disease. Best Pract Res Clin Gastroenterol. 2013; 27: 471

29）Kumar AS, Devi G, Kar P, et al. Association of cytokines in hepatitis E with pregnancy outcome. Cytokine. 2014; 65: 95-104

30）Steuerwald NM, Foureau RJ, Norton HJ. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One. 2013; 8: e81974

31）荒田慎寿，森脇義弘，高山和久，他．急性肝不全に対するon-line hemodiafiltration を用いた人工肝補助療法の確立．肝臓．2012; 53: 7-17

32）藤原慶一，織田成人，井上和明，他．急性肝不全に対する人工肝補助療法についての提言: high-flow CHDF, on-line HDFによる覚醒率向上の認識とその全国標準化の必要性．肝臓　Meeting Report. 2014; 55: 79-81

33）Pu Y, Yang D, Mao Y, et al. Therapeutic effects of blood purification in treatment of fulminant hepatic failure. Braz J Infect Dis. 2013; 17: 427-30

34）Benares R, Nevens F, Larsen S. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF Trial. Hepatology. 2013; 57: 1153-62

35）Nevens F, Laleman W. Artificial liver support devices as treatment option for liver failure. Best Pract Res Clin Gastroenterol. 2012; 26: 17-26

36）Wang DW, Yin YM, Yao YM, et al. Advances in the management of acute liver failure. World J Gastroenterol. 2013; 19: 7069-77

37）Wlodzimirow KA, Eslami S, Chamuleau RA, et al. Prediction of poor outcome in patients with acute liver failure-systematic review of prediction models. PLoS One. 2012; 7: e50952

38）Warrillow SJ, Bellomo R. Preventing cerebral oedema in acute liver failure: the case for quadruple-H therapy. Anaesth Intensive Care. 2014; 42: 78-88

39）Karvellas CJ, Fix OK, Battenhouse H, et al. Outcomes and complications of intracranial pressure monitoring in acute liver failure: a retrospective cohort study. Crit Care Med. 2014; 42: 1157-67

40）Singh SL, Hynan S, Lee WM. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci. 2013; 58: 1397-402

41）Sales I, Dzierba AL, Smithburger PL, et al. Use of acetylcysteine for non-acetaminophen-induced acute liver failure. Ann Hepatol. 2013; 12: 6-10

42）鈴木一幸，滝川康裕，宮本康弘，他．急性肝障害の劇症化率と劇症化予防に対するN-アセチルシステインの効果に関する研究．厚生労働省科学研究費補助金（難治性疾患克服対策事業）「難治性の肝・胆道疾患に関する調査研究班」平成24年度報告書．2013. p.131-4

43）肝移植研究会．肝移植症例報告．移植．2014; 47: 416-28

44）Yamashiki N, Sugawara Y, Tamura S, et al. Outcomes after living donor liver transplantation for acute liver failure in Japan. Liver Transpl. 2012; 18: 1069-77

45）Kaido T, Tomiyama K, Ogawa K, et al. Living donor liver transplantation for patients with high model for end-stage liver disease scores and acute liver failure. Transplantation. 2014; 97(suppl8): S46-7

46）Hoyer DP, Munteanu M, Canbay A, et al. Liver transplantation for acute liver failure: are there thresholds not to be crossed? Transpl Int. 2014; 27: 625-33

47）Urrunaga NH, Rachakonda VP, Magder LS, et al. Outcomes of living versus deceased donor liver transplantation for acute liver failure in the United States. Transplant Proc. 2014; 46: 219-24

48）Wlodzimirow KA, Eslami S, Chamuleau RA, et al. Prediction of poor outcome in patients with acute liver failure-systematic review of prediction models. PLoS One. 2012; 7: e50952

49）Bala L, Mehrotra M, Mohindra S, et al. Early prognostic markers for fatal fulminant hepatic failure cases with viral hepatitis: proton nuclear magnetic resonance spectroscopic studies of serum. Dig Liver Dis. 2013; 45: 155-63

50）Saliba F, Samuel D. Acute liver failure: current trends. J Hepatol. 2013; 59: 6-8

51）Craig DG, Simpson KJ. Accuracy of the ALFSG index as a triage marker in acute liver failure. Gastroenterology. 2013; 144: e25

52）Majumdar M, Ratho R, Chawla Y, et al. High levels of circulating HMGB1 as a biomarker of acute liver failure in patients with viral hepatitis E. Liver Int. 2013; 33: 1341-8

53）Roth GA, Nickl S, Lebherz-Eichinger D, et al. Lipocalin-2 serum levels are increased in acute hepatic failure. Transplant Proc. 2013; 45: 241-4

54）Stravitz RT, Bowling R, Bradford R, et al. Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure. Hepatology. 2013; 58: 304-13

55）Tatsumi H, Masuda Y, Imaizumi H, et al. Asialoglycoprotein receptor scintigraphy with 99mTc-galactosyl human serum albumin (99mTc-GSA) as an early predictor of survival in acute liver failure. Anaesth Intensive Care. 2013; 41: 523-8

56）Lock JF, Kotobi AN, Malinowski M, et al. Predicting the prognosis in acute liver failure: results from a retrospective pilot study using the LiMAx test. Ann Hepatol. 2013; 12: 556-62

57）Fikatas P, Lee JE, Sauer M, et al. APACHE III score is superior to Kingʼs College Hospital criteria, MELD score and APACHE II score to predict outcomes after liver transplantation for acute liver failure. Transplant Proc. 2013; 45: 2295-301

58）Poddar B, Saigal S, Kumar A, et al. Factors associated with outcome in acute liver failure in an intensive care unit. Indian J Gastroenterol. 2013; 32: 172-8

59）持田　智，中山伸朗，桶谷　真，他．劇症肝炎における高精度予後予測システムの実用化: 平成24年度全国調査．厚生労働省科学研究費補助金（難治性疾患克服対策事業）「難治性の肝・胆道疾患に関する調査研究班」平成24年度報告書．2013. p.125-8

60）Rajanayagam J, Frank E, Shepherd R, et al. Artificial neural network is highly predictive of outcome in paediatric acute liver failure. Pediatr Transplant. 2013; 17: 535-42

61）Watanabe RT, Ishii T, Kobayashi H, et al. Prevalence of hepatitis B virus infection in patients with rheumatic diseases in tohoku area: a retrospective multicenter survey. Tohoku J Exp Med. 2014; 233: 129-33

62）Dong HJ, Ni LN, Sheng GF, et al. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol. 2013; 57: 209-14

63）Kim SJ, Hsu S, Song YQ, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer. 2013; 49: 3486-96

64）Ling WH, Soe PP, Pang AS, et al. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer. 2013; 108: 1931-5

65）Zheng Y, Zhang S, Tan Grahn HM, et al. Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis. Hepat Mon. 2013; 13: e6496

66）Harigai M, Mochida S, Mimura T, et al. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. Mod Rheumatol. 2014; 24: 1-7

67）Loras C, Gisbert JP, Piqueras M, et al. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3). J Crohns Colitis. 2014; 8: 1529-38

68）Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013; 31: 2765-72

69）中谷　綾，林　美奈，新田祐子，他．「免疫抑制・化学療法により発症するB型肝炎対策のガイドライン」は徹底されているか？　癌と化学療法．2014; 41: 523-5

70）Sampedro B, Hernandez-Lopez C, Ferrandiz JR, et al. Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project. Hepatology. 2014; 60: 106-13

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp